Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$48.37 USD
-0.48 (-0.98%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $48.17 -0.20 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Akero Therapeutics, Inc. has a market cap of $3.89B, which represents its share price of $48.85 multiplied by its outstanding shares number of 79.72M. As a mid-cap company, AKRO's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AKRO 48.37 -0.48(-0.98%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Other News for AKRO
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
Insider Sell: Andrew Cheng Sells 30,000 Shares of Akero Therapeutics Inc (AKRO)
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Target | AKRO Stock News